Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Purchased by State Street Corp

State Street Corp grew its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 11.7% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 5,148,293 shares of the company's stock after buying an additional 539,936 shares during the period. State Street Corp owned approximately 5.08% of Neurocrine Biosciences worth $593,186,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in the company. CWM LLC boosted its position in Neurocrine Biosciences by 46.8% in the second quarter. CWM LLC now owns 6,849 shares of the company's stock worth $943,000 after purchasing an additional 2,185 shares during the last quarter. SG Americas Securities LLC bought a new stake in shares of Neurocrine Biosciences during the 2nd quarter valued at $5,848,000. Sequoia Financial Advisors LLC purchased a new position in Neurocrine Biosciences during the second quarter valued at $207,000. Wealth Enhancement Advisory Services LLC grew its holdings in Neurocrine Biosciences by 34.0% during the second quarter. Wealth Enhancement Advisory Services LLC now owns 6,357 shares of the company's stock valued at $875,000 after purchasing an additional 1,613 shares during the period. Finally, V Square Quantitative Management LLC bought a new position in shares of Neurocrine Biosciences in the second quarter worth about $184,000. Hedge funds and other institutional investors own 92.59% of the company's stock.

Neurocrine Biosciences Stock Performance

NBIX traded up $0.98 during trading on Monday, hitting $129.12. The stock had a trading volume of 682,433 shares, compared to its average volume of 869,242. The stock has a 50 day simple moving average of $120.33 and a two-hundred day simple moving average of $130.98. Neurocrine Biosciences, Inc. has a twelve month low of $110.95 and a twelve month high of $157.98. The company has a market capitalization of $13.07 billion, a PE ratio of 34.35 and a beta of 0.34.

Analysts Set New Price Targets

Several equities analysts recently weighed in on the stock. Raymond James reaffirmed an "outperform" rating and set a $155.00 target price on shares of Neurocrine Biosciences in a research note on Thursday, October 10th. Cantor Fitzgerald restated an "overweight" rating and issued a $155.00 price target on shares of Neurocrine Biosciences in a research report on Monday, September 16th. StockNews.com cut shares of Neurocrine Biosciences from a "strong-buy" rating to a "buy" rating in a research note on Friday, November 1st. Jefferies Financial Group upped their target price on shares of Neurocrine Biosciences from $177.00 to $189.00 and gave the company a "buy" rating in a research report on Monday, August 19th. Finally, BMO Capital Markets reduced their price objective on Neurocrine Biosciences from $128.00 to $114.00 and set a "market perform" rating on the stock in a research note on Thursday, October 17th. Five research analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $163.91.

Insider Buying and Selling

In other news, insider Jude Onyia sold 2,331 shares of the business's stock in a transaction on Friday, November 29th. The shares were sold at an average price of $126.29, for a total transaction of $294,381.99. Following the sale, the insider now directly owns 15,449 shares of the company's stock, valued at $1,951,054.21. The trade was a 13.11 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 4.30% of the stock is owned by company insiders.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.